Though further investigation of the relationships of RELMβ with metabolic parameters in humans is needed, the data accumulated thus far suggest that suppressing gut-derived RELMβ expression by approaches such as gut microbiota modification might be a therapeutic strategy for managing NAFLD/NASH. Here, RETNLB is linked to metabolic dysfunction-associated steatohepatitis.